11:54 AM EDT, 04/24/2026 (MT Newswires) -- Damora Therapeutics ( DMRA ) is capitalizing on growing validation of using mutant calreticulin targeting therapies in myeloproliferative neoplasms, and may have the additional advantage of a

charted regulatory path as a fast-follower over Incyte's ( INCY ) mid-stage candidate, RBC Capital said in a note emailed Friday.

RBC said data from Incyte's ( INCY ) CALR antibody program have helped reduce uncertainty around the mechanism, strengthening confidence in its potential for treating conditions such as essential thrombocythemia and myelofibrosis.

Damora's lead candidate DMR-001 may offer advantages such as extended half-life via YTE technology, higher potency, and a more consistent activity profile across mutation types, potentially addressing limitations of competing therapies, according to the report.

The analyst sees DMR-001 reaching about $1.7 billion in peak U.S. potential, supported by improved dosing convenience and broader applicability, with a 60% probability of success in essential thrombocythemia and 35% in myelofibrosis.

The firm said it expects the company's shares to appreciate to levels reflecting its long-term top-line potential.

The report added that competitive clinical readouts could help de-risk the program, with early mid-2027 data viewed as a key potential catalyst for upside.

RBC initiated the coverage on the company with an outperform rating on the stock with a price target of $40.

Price: 24.02, Change: -1.40, Percent Change: -5.51